ACHIEVE LIFE SCIENCES, INC. Logo

ACHIEVE LIFE SCIENCES, INC.

Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.

ACHV | US

Overview

Corporate Details

ISIN(s):
US0044685008
LEI:
Country:
United States of America
Address:
22722 29TH DR. SE, 98021 SEATTLE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company dedicated to addressing the global nicotine dependence epidemic. The company's core focus is the development and commercialization of its lead product candidate, cytisinicline, a plant-based alkaloid intended for smoking cessation and nicotine addiction. Following two successful Phase 3 studies, the company's New Drug Application (NDA) for cytisinicline was accepted for review by the U.S. Food and Drug Administration (FDA). If approved, cytisinicline has the potential to become the first new FDA-approved treatment option for smoking cessation in nearly two decades.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ACHIEVE LIFE SCIENCES, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ACHIEVE LIFE SCIENCES, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ACHIEVE LIFE SCIENCES, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel
PLUR
PLUS THERAPEUTICS, INC. Logo
Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.
United States of America
PSTV
PMV Pharmaceuticals, Inc. Logo
Developing small molecule therapies targeting p53 mutations to treat cancer.
United States of America
PMVP
A global supplier of generic APIs using AI to accelerate drug development.
South Korea
041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland
PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland
PPGN
PolyPid Ltd. Logo
Develops localized, prolonged-release drug therapies for surgery, oncology & metabolic diseases.
United States of America
PYPD
Praxis Precision Medicines, Inc. Logo
Developing therapies for CNS disorders using insights from genetic epilepsies.
United States of America
PRAX
PRECIGEN, INC. Logo
Develops gene and cell therapies for difficult-to-treat diseases using precision technology.
United States of America
PGEN
Precipio, Inc. Logo
Provides blood cancer diagnostic services & products to improve accuracy for physicians & labs.
United States of America
PRPO

Talk to a Data Expert

Have a question? We'll get back to you promptly.